Amgen Drug Shows Promise in Sjögren’s Disease Phase 3 Trial
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Amgen Inc.’s experimental drug helped patients with moderate-to-severe Sjögren’s disease in a late-stage trial, advancing a potential therapy for the chronic autoimmune condition that has no approved treatment.
Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.
Amgen
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Amgen Inc.’s experimental drug helped patients with moderate-to-severe Sjögren’s disease in a late-stage trial, advancing a potential therapy for the chronic autoimmune condition that has no approved treatment.”
Bloomberg — Amgen Drug May Offer Sjögren’s Patients First Effective Therapy“Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.”
IBD — Amgen Boasts Success In Sjogren's; Shares Charge Ahead“An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far struggled to gain traction.”
fierce biotech — <a href="/biotech/amgens-horizon-acquired-fusion-protein-eases-sjogrens-severity-ph-3-win" hreflang="en">Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win</a>